Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy

Prior treatment

• Treatment started prior to inclusion

Other

• CML in accelerated or blast phase
• Refusal to participate in the study
• Patients under guardianship, curatorship, deprivation of liberty or safeguard of justice
• Pregnant or breast-feeding women

• Age ≥18 years
• CML in chronic phase at time of diagnosis. Diagnosis must be made no more than 3 months (90 days) prior to inclusion. Diagnosis of chronic-phase CML (European Leukemia Network \[ELN\] 2020 criteria; Baccarani et al 2013) with confirmation of a Philadelphia chromosome (Ph1). A cryptic Ph1 chromosome must be confirmed by FISH.Criteria must meet the definition of chronic phase CML
• BCR ::ABL1 transcript quantifiable by quantitative PCR
• 1st-line treatment with tyrosine kinase inhibitor
• No tyrosine kinase inhibitor or hydroxyurea treatment received prior to first blood sampling (at diagnosis)
• Signature of informed consent for CML Observatory and signature of informed consent for BIO-TIMER protocol
• Read and understand French
• Enrolled in a social security plan or beneficiary of such a plan